RTP Mobile Logo
Real-Life Decisions: An Interactive Case-Based Symposium on the Management of Multiple Myeloma, Myelodysplastic Syndromes and Acute Myeloid Leukemias
Released May 2011

A comprehensive online training resource and self-directed educational activity featuring discussions of individual patient cases, didactic faculty presentations reviewing the published research data and ongoing trials addressing optimal treatment in each clinical situation presented, assessment of the use of current data in the management of each case and interpretation of any homogeneity/heterogeneity observed in premeeting survey results.

CE Disclosures and Faculty Information


    This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of multiple myeloma (MM), myelodysplastic syndromes (MDS) and acute myeloid leukemias.

    • Appraise recent data on therapeutic advances and changing practice standards in acute myeloid leukemia (AML)/acute promyelocytic leukemia (APL) and MDS, and integrate this information into current clinical care when appropriate.
    • Apply the results of emerging clinical research to the selection of optimal systemic therapy for patients with newly diagnosed and relapsed/refractory MM.
    • Develop an algorithm for risk-stratified induction therapy for patients with AML or APL.
    • Identify patients with AML or MM who may experience quantitative and qualitative benefit from stem cell transplantation.
    • Use prognostic and predictive clinical and molecular markers to aid in risk stratification and treatment decision-making for MDS.
    • Employ case-based learning to individualize the use of maintenance and/or consolidation therapy in the management of AML/APL and MM.
    • Recall the emerging data for novel agents and combinations in the treatment of MM.
    • Offer evidence-based supportive management strategies to facilitate tolerability and adherence to systemic treatments for AML/APL, MDS and MM.
    • Integrate patient perspectives on the challenges of a hematologic cancer diagnosis and its treatment into the comprehensive clinical decision-making process.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity consists of a video component. The participant should watch the video content.


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    William I Bensinger, MD
    Professor of Medicine
    University of Washington
    Member, Fred Hutchinson
    Cancer Research Center
    Seattle, Washington

    Advisory Committee: Millennium — The Takeda Oncology Company, Onyx Pharmaceuticals Inc; Consulting Agreements: Amgen Inc, Celgene Corporation, Genzyme Corporation; Paid Research: AstraZeneca Pharmaceuticals LP, Facet Biotech Corporation, Genentech BioOncology, Millennium — The Takeda Oncology Company, Onyx Pharmaceuticals Inc; Speakers Bureau: Celgene Corporation.

    Pierre Fenaux, MD

    Professor of Hematology
    Hôpital Avicenne
    University Paris 13
    Bobigny, France

    Advisory Committee: Bristol-Myers Squibb Company, Cephalon Inc, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc; Consulting Agreement and Paid Research: Celgene Corporation.

    Paul A S Fishkin, MD

    Illinois CancerCare
    Peoria, Illinois

    Stock Ownership: Biogen Idec.

    William N Harwin, MD
    Florida Cancer Specialists
    Fort Myers, Florida

    No real or apparent conflicts of interest to disclose.

    Morie A Gertz, MD
    Professor and Chair
    Department of Medicine
    Mayo Clinic
    Rochester, Minnesota

    Advisory Committee: Celgene Corporation, Eisai Inc, Millennium — The Takeda Oncology Company.

    Farhad Ravandi, MD
    Associate Professor of Medicine
    Department of Leukemia
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Cephalon Inc, Eisai Inc, EMD Serono Inc, Genzyme Corporation, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Schering-Plough Corporation; Speakers Bureau: Cephalon Inc, Eisai Inc, Novartis Pharmaceuticals Corporation.

    Michael A Schwartz, MD
    Attending, Mount Sinai
    Medical Center
    Miami Beach, Florida

    No real or apparent conflicts of interest to disclose.

    B Douglas Smith, MD
    Associate Professor of Oncology
    The Sidney Kimmel Comprehensive
    Cancer Center at Johns Hopkins
    Baltimore, Maryland

    Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Novartis Pharmaceuticals Corporation; Paid Research: Eisai Inc, Infinity Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Synta Pharmaceuticals Corp.

    Ravi Vij, MD
    Associate Professor of Medicine
    Washington University School of Medicine
    Section of Stem Cell Transplant and Leukemia
    Division of Medical Oncology
    St Louis, Missouri

    Consulting Agreement: Onyx Pharmaceuticals Inc; Speakers Bureau: Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Eisai Inc, Genzyme Corporation, GlaxoSmithKline, Millennium — The Takeda Oncology Company.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium — The Takeda Oncology Company, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.

    — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This program is supported by an educational grant from Celgene Corporation.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: May 2011
    Expiration date: May 2012

    This presentation was selected by the American Society of Hematology® as an independent educational activity held adjunct to the ASH Annual Meeting. This presentation is not sponsored or endorsed by ASH.


Acknowledge and close

Watch video
(WIFI is recommended for best performance):